Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Camptosar irinotecan: Phase III data; marketed as second-line therapy

Researchers published in The Lancet results of a European Phase III trial comparing

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE